Sodium/glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of both cardiovascular death and hospitalization for HF in patients with HF, regardless of diabetes mellitus7–11. Here, SLC5A2 is linked to diabetes mellitus.